Literature DB >> 3677123

Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

G M Stuhlmiller1, T L Darrow, D M Haupt, H F Seigler.   

Abstract

Melanoma high molecular weight tumor-associated antigen (TAA), having a molecular weight of 250 kilodaltons (Kd), was purified from a crude cell membrane extract through a combination of lectin affinity, immunoadsorption, and high performance liquid molecular filtration chromatography. Compared to the starting extract, purified TAA was 600-fold higher in TAA activity per microgram of protein. Purified TAA was used to immunize a chimpanzee and the resulting antiTAA immune response was evaluated. Postimmune chimpanzee serum reacted in solid phase radioimmunoassay against purified TAA with a titer in excess of 100,000. In contrast, preimmune serum had a titer of less than 100 in the same assay. By immunoprecipitation analysis, we were able to demonstrate reactivity of the chimpanzee immune serum with a 250 Kd TAA in spent culture medium from melanoma cells metabolically labeled with 35S-methionine and with iodinated purified 250 Kd TAA. Reactivity of the chimpanzee antiserum for the 250 Kd TAA was confirmed in blocking and reciprocal immunodepletion studies using murine monoclonal antibody 9.2.27. These studies suggest that the 250 Kd TAA defined by murine monoclonal antibodies may prove to be immunogenic in man and that manipulation of the immune response to this TAA might be used to the clinical benefit of the patient.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677123     DOI: 10.1007/bf00199147

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

Review 1.  Current management of melanoma.

Authors:  H F Seigler; B F Fetter
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

2.  Common human melanoma-associated antigen(s) detected by monoclonal antibodies.

Authors:  S Carrel; R S Accolla; A L Carmagnola; J P Mach
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

3.  Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells.

Authors:  J R Harper; T F Bumol; R A Reisfeld
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

4.  Mouse monoclonal antibody to a melanoma-carcinoma-associated antigen synthesized by a human melanoma cell line propagated in serum-free medium.

Authors:  D O Chee; R H Yonemoto; S P Leong; G F Richards; V R Smith; J L Klotz; R M Goto; R L Gascon; M M Drushella
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

5.  Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.

Authors:  W A Cassel; D R Murray; A H Torbin; Z L Olkowski; M E Moore
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

6.  Human melanoma-specific oncofetal antigen defined by a mouse monoclonal antibody.

Authors:  S K Liao; B J Clarke; M Khosravi; P C Kwong; A Brickenden; P B Dent
Journal:  Int J Cancer       Date:  1982-11-15       Impact factor: 7.396

7.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

Authors:  W G Dippold; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

9.  Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin.

Authors:  J P Johnson; M Demmer-Dieckmann; T Meo; M R Hadam; G Riethmüller
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  2 in total

1.  Serological response of non-human primates to human melanoma disialoganglioside GD3.

Authors:  G M Stuhlmiller; K M Roberson; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Natural pathology of the captive chimpanzee (Pan troglodytes): A 35-year review.

Authors:  Shyamesh Kumar; Hannah Laurence; Michael A Owston; R Mark Sharp; Priscilla Williams; Robert E Lanford; Gene B Hubbard; Edward J Dick
Journal:  J Med Primatol       Date:  2017-05-23       Impact factor: 0.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.